EGFR and central nervous system cancer: The 2021 CAP guidelines on molecular biomarker testing for the diagnosis of glioblastoma (GBM) uses EGFR amplification, TERT promoter mutation status, and gain of chromosome 7 with concurrent loss of chromosome10 to help diagnose gliomas that lack necrosis or microvascular proliferation.